home / stock / bysi / bysi news

BYSI News and Press, BeyondSpring Inc. From 03/13/23

Stock Information
Company Name: BeyondSpring Inc.
Stock Symbol: BYSI
Market: NASDAQ
Website: beyondspringpharma.com
Menu
BYSI BYSI Quote BYSI Short BYSI News BYSI Articles BYSI Message Board
Get BYSI Alerts

News, Short Squeeze, Breakout and More Instantly...
BYSI - Provention, Caleminder top healthcare gainers; Cingulate, iCAD among losers

2023-03-13 10:02:38 ET Gainers: Provention Bio PRVB +248% . Caleminder ( CMND ) +38% . Calliditas Therapeutics ( CALT ) +32% . Euda Health ( EUDA ) +22% . Seagen  ( SGEN ) +15% . Losers: Cingulate CING -28...
BYSI - The Charles Schwab, Banco Santander, First Republic among major financials premarket losers' pack

2023-03-13 08:57:19 ET First Republic FRC -64% amid woes regarding SVB, Signature collapse . Western Alliance WAL -54% amid woes regarding SVB, Signature collapse . PacWest PACW -40% amid woes regarding SVB, Signature collapse . Euda Health ( EUDA...

BYSI - BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that the first patient has been...

BYSI - BeyondSpring regains Nasdaq compliance on minimum bid price

Clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, BeyondSpring ( NASDAQ: BYSI ) received a written notification from Nasdaq that the company has regained compliance with the minimum bid price requirement. Nasdaq has determined ...
BYSI - BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that on December 29, 2022, the C...

BYSI - BeyondSpring rises 18% on positive data from trial of plinabulin to prevent docetaxel-induced neutropenia in NSCLC patients

BeyondSpring ( NASDAQ: BYSI ) is trading ~18% higher after the company announced positive data from trial of lead asset, plinabulin, to prevent docetaxel-induced neutropenia in non-small cell lung cancer (NSCLC) patients. The analyses showed the efficacy of plinabulin as a mon...

BYSI - BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences

Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy in reducing the mean duration of severe neutropenia (DSN) for patients receiving docetaxel In an analysis of breast cancer patients, plinabulin monotherapy was superior vs no...
BYSI - BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that on November 18, 2022,...

BYSI - BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who ...

BYSI - BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting

NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who h...
Previous 10 Next 10